Active Ingredient History
Belinostat is a hydroxamate-type histone deacetylase inhibitor indicated for the treatment of relapsed or refractory peripheal T-cell lymphoma. The compound received orphan drug designation for the treatment of malignant thymomas. Acting on a histone deacetylase Belinostat causes the accumulation of acetylated histones and other proteins, inducing cell cycle arrest and/or apoptosis of some transformed cells. Belinostat targets HDAC enzymes, thereby inhibiting tumor cell proliferation, inducing apoptosis, promoting cellular differentiation, and inhibiting angiogenesis. This agent may sensitize drug-resistant tumor cells to other antineoplastic agents, possibly through a mechanism involving the down-regulation of thymidylate synthase. PXD101 has been shown in preclinical studies to have the potential to treat a wide range of solid and hematologic malignancies either as a monotherapy or in combination with other active agents, and both an oral and intravenous formulation of the drug are being evaluated in clinical trials. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Breast Neoplasms (Phase 1)
Brenner Tumor (Phase 2)
Burkitt Lymphoma (Phase 2)
Carcinoma (Phase 2)
Carcinoma, Hepatocellular (Phase 1/Phase 2)
Carcinoma, Neuroendocrine (Phase 1)
Carcinoma, Non-Small-Cell Lung (Phase 1/Phase 2)
Carcinoma, Ovarian Epithelial (Phase 1/Phase 2)
Carcinoma, Transitional Cell (Phase 1)
Chondrosarcoma (Phase 2)
Fallopian Tube Neoplasms (Phase 2)
Glioblastoma (Phase 2)
Hamartoma (Phase 2)
Hematologic Neoplasms (Phase 1)
Hodgkin Disease (Phase 1)
Intraocular Lymphoma (Phase 1)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)
Leukemia-Lymphoma, Adult T-Cell (Phase 2)
Leukemia, Myeloid, Acute (Phase 2)
Leukemia, Myeloid, Chronic-Phase (Phase 1)
Leukemia, Myelomonocytic, Chronic (Phase 1)
Liver Neoplasms (Phase 1/Phase 2)
Lymphoma (Phase 1/Phase 2)
Lymphoma, B-Cell, Marginal Zone (Phase 1)
Lymphoma, Follicular (Phase 1)
Lymphoma, Large B-Cell, Diffuse (Phase 1)
Lymphoma, Large-Cell, Anaplastic (Phase 2)
Lymphoma, Large-Cell, Immunoblastic (Phase 2)
Lymphoma, Mantle-Cell (Phase 2)
Lymphoma, Non-Hodgkin (Phase 2)
Lymphoma, T-Cell (Phase 1)
Lymphoma, T-Cell, Cutaneous (Phase 2)
Lymphomatoid Granulomatosis (Phase 1)
Melanoma (Phase 2)
Mesothelioma (Phase 2)
Multiple Myeloma (Phase 2)
Mycosis Fungoides (Phase 1)
Myelodysplastic Syndromes (Phase 2)
Myeloproliferative Disorders (Phase 1)
Neoplasm Metastasis (Phase 1)
Neoplasms ()
Ovarian Neoplasms (Phase 2)
Primary Myelofibrosis (Phase 1)
Sarcoma (Phase 1/Phase 2)
Sezary Syndrome (Phase 1)
Small Cell Lung Carcinoma (Phase 1)
Thymoma (Phase 2)
Transplantation (Phase 1)
Urinary Bladder Neoplasms (Phase 1/Phase 2)
Waldenstrom Macroglobulinemia (Phase 1)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue